Alloy Therapeutics and Swiss Rockets Group Launch Collaboration to Advance Next‑Gen Radioligand Cancer Therapies
Swiss Rockets AG and Alloy Therapeutics entered into a Master Research Agreement to jointly discover and develop next‑generation radioligand therapeutics (RLTs) for oncology, combining Alloy’s antibody discovery and engineering platforms with Swiss Rockets’ radiopharmaceutical development expertise including Terbium‑161. The collaboration aims to generate novel targeted RLT candidates across multiple oncology targets and accelerate their progression toward clinical development. 
Alloy Therapeutics and Swiss Rockets Group Launch Collaboration to Advance Next‑Gen Radioligand Cancer Therapies